These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 30255938)

  • 1. Identification of a highly lethal V3
    Christopoulos P; Kirchner M; Bozorgmehr F; Endris V; Elsayed M; Budczies J; Ristau J; Penzel R; Herth FJ; Heussel CP; Eichhorn M; Muley T; Meister M; Fischer JR; Rieken S; Lasitschka F; Bischoff H; Sotillo R; Schirmacher P; Thomas M; Stenzinger A
    Int J Cancer; 2019 Jan; 144(1):190-199. PubMed ID: 30255938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK
    Christopoulos P; Endris V; Bozorgmehr F; Elsayed M; Kirchner M; Ristau J; Buchhalter I; Penzel R; Herth FJ; Heussel CP; Eichhorn M; Muley T; Meister M; Fischer JR; Rieken S; Warth A; Bischoff H; Schirmacher P; Stenzinger A; Thomas M
    Int J Cancer; 2018 Jun; 142(12):2589-2598. PubMed ID: 29363116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC.
    Zhang SS; Nagasaka M; Zhu VW; Ou SI
    Lung Cancer; 2021 Aug; 158():126-136. PubMed ID: 34175504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK-rearranged non-small-cell lung cancer.
    Song P; Zhang F; Li Y; Yang G; Li W; Ying J; Gao S
    Cancer Med; 2019 Apr; 8(4):1551-1557. PubMed ID: 30843662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to crizotinib in advanced ALK-rearranged non-small cell lung cancers with different ALK-fusion variants.
    Li Y; Zhang T; Zhang J; Li W; Yuan P; Xing P; Zhang Z; Chuai S; Li J; Ying J
    Lung Cancer; 2018 Apr; 118():128-133. PubMed ID: 29571990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
    Qin K; Hou H; Liang Y; Zhang X
    BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations.
    Bearz A; Martini JF; Jassem J; Kim SW; Chang GC; Shaw AT; Shepard DA; Dall'O' E; Polli A; Thurm H; Zalcman G; Garcia Campelo MR; Penkov K; Hayashi H; Solomon BJ
    J Thorac Oncol; 2023 Nov; 18(11):1581-1593. PubMed ID: 37541389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic instability and recurrent MYC amplification in ALK-translocated NSCLC: a central role of TP53 mutations.
    Alidousty C; Baar T; Martelotto LG; Heydt C; Wagener S; Fassunke J; Duerbaum N; Scheel AH; Frank S; Holz B; Binot E; Kron A; Merkelbach-Bruse S; Ihle MA; Wolf J; Buettner R; Schultheis AM
    J Pathol; 2018 Sep; 246(1):67-76. PubMed ID: 29885057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
    Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R
    Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.
    Peters S; Zimmermann S
    Curr Treat Options Oncol; 2018 May; 19(7):37. PubMed ID: 29808239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
    Cha YJ; Kim HR; Shim HS
    J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALK fusion small cell transformation of lung adenocarcinoma: A case report and literature review.
    Xu G; Zhou L
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2024 Apr; 49(4):628-636. PubMed ID: 39019792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distribution of EML4-ALK fusion variants and clinical outcomes in patients with resected non-small cell lung cancer.
    Tao H; Shi L; Zhou A; Li H; Gai F; Huang Z; Che N; Liu Z
    Lung Cancer; 2020 Nov; 149():154-161. PubMed ID: 33017727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transforming tumoroids derived from ALK-positive pulmonary adenocarcinoma to squamous cell carcinoma in vivo.
    Yokota E; Iwai M; Ishida Y; Yukawa T; Matsubara M; Naomoto Y; Fujiwara H; Monobe Y; Haisa M; Takigawa N; Fukazawa T; Yamatsuji T
    Hum Cell; 2024 Jul; 37(4):1132-1140. PubMed ID: 38829559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.
    Lin JJ; Zhu VW; Yoda S; Yeap BY; Schrock AB; Dagogo-Jack I; Jessop NA; Jiang GY; Le LP; Gowen K; Stephens PJ; Ross JS; Ali SM; Miller VA; Johnson ML; Lovly CM; Hata AN; Gainor JF; Iafrate AJ; Shaw AT; Ou SI
    J Clin Oncol; 2018 Apr; 36(12):1199-1206. PubMed ID: 29373100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Lung Squamous Cell Carcinoma with EML4-ALK Fusion and TP53 Co-mutation 
Treated with Ensartinib: A Case Report and Literature Review].
    Lv D; Xu C; Wang C; Sang Q
    Zhongguo Fei Ai Za Zhi; 2023 Jan; 26(1):78-82. PubMed ID: 36792084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Tumor-intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK-positive NSCLC.
    Nakazawa M; Harada G; Ghanem P; Bubie A; Kiedrowski LA; Murray JC; Marrone KA; Scott SC; Houseknecht S; Falcon CJ; Evans P; Feliciano J; Hann CL; Ettinger DS; Smith KN; Anagnostou V; Forde PM; Brahmer JR; Levy B; Drilon A; Lam VK
    Cancer Res Commun; 2024 Mar; 4(3):786-795. PubMed ID: 38407352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer.
    Yu Y; Ou Q; Wu X; Bao H; Ding Y; Shao YW; Lu S
    Lung Cancer; 2019 Jan; 127():19-24. PubMed ID: 30642546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK-Positive Human Non-Small Cell Lung Cancer.
    Pyo KH; Lim SM; Kim HR; Sung YH; Yun MR; Kim SM; Kim H; Kang HN; Lee JM; Kim SG; Park CW; Chang H; Shim HS; Lee HW; Cho BC
    J Thorac Oncol; 2017 Mar; 12(3):491-500. PubMed ID: 27836576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.
    Inamura K; Takeuchi K; Togashi Y; Nomura K; Ninomiya H; Okui M; Satoh Y; Okumura S; Nakagawa K; Soda M; Choi YL; Niki T; Mano H; Ishikawa Y
    J Thorac Oncol; 2008 Jan; 3(1):13-7. PubMed ID: 18166835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.